Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.39 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17420502 | 0.87 | ALDH1A1 (0.47) | POLBABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL17583161 | 0.85 | ALDH1A1 (0.39) | POLBABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL17420547 | 0.85 | ACACB (0.39) | POLBABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL21745527 | 0.84 | PLAAT3 (0.41) | ALDH1A1 | |
| SCHEMBL14466833 | 0.83 | KCNQ3 (0.42) | POLBL3MBTL1NPC1RAB9AGAA | |
| SCHEMBL3891001 | 0.82 | KDM4E (0.48) | POLBCYP1A2CYP3A4MAPTKMT2A | |
| SCHEMBL161047 | 0.81 | MAPT (0.42) | POLBCYP1A2MAPTMEN1KMT2A | |
| SCHEMBL17113764 | 0.81 | POLB (0.49) | POLBTSHRMAPTL3MBTL1NPC1 | |
| SCHEMBL20406093 | 0.81 | KMT2A (0.41) | POLBMAPTKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL14332032 | 0.80 | HTT (0.46) | POLBABCB11CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548903-B2 | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use | AMGEN INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11548903-B2 | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use | AMGEN INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-3555106-B1 | BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC (US) | 2022-03-09 | — | — | EP | disclosed |
| US-11021493-B2 | 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use | AMGEN INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-11021493-B2 | 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use | AMGEN INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200231601-A1 | 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2020-07-23 | — | — | US | disclosed |
| US-20200231601-A1 | 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2020-07-23 | — | — | US | disclosed |
| US-20200199153-A1 | BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2020-06-25 | — | — | US | disclosed |
| US-20200199153-A1 | BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2020-06-25 | — | — | US | disclosed |
| EP-3555086-A1 | 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20180303834-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2018-10-25 | — | — | US | disclosed |
| WO-2018112084-A1 | BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018112094-A1 | 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| US-9968610-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (US) | 2018-05-15 | — | — | US | disclosed |
| US-9968610-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170209449-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-07-27 | — | — | US | disclosed |
| US-20170209449-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-07-27 | — | — | US | disclosed |
| US-9567341-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-02-14 | — | — | US | disclosed |
| US-9567341-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-02-14 | — | — | US | disclosed |
| US-20160075713-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199153-A1 | BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | POLB 1662/4885ABCB11 2365/4885CYP1A2 745/4885 |
| US-20170209449-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN1, GRIN2A, GRIN2B | POLB 2316/4885ABCB11 2791/4885CYP1A2 1581/4885 |
| US-20200231601-A1 | 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | POLB 2148/4885ABCB11 4203/4885CYP1A2 128/4885 |
| US-11021493-B2 | 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use | BACE1, BACE2, APP | POLB 2148/4885ABCB11 4203/4885CYP1A2 128/4885 |
| US-20160075713-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN1, GRIN2A, GRIN2B | POLB 2316/4885ABCB11 2791/4885CYP1A2 1581/4885 |
| US-11548903-B2 | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use | BACE1, BACE2, APP | POLB 1662/4885ABCB11 2365/4885CYP1A2 745/4885 |
| US-20180303834-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN1, GRIN2A, GRIN2B | POLB 2316/4885ABCB11 2791/4885CYP1A2 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.